Toevaluatethe anti-sepsispotentialofYC-1,wehaveexamined the effectof YC-1 on theregulationofcytokine production in humanl eukocytesand endotoxemicmice. The datademonstrated thatYC-1 showed apreferentialinhibitiononproinflammatory cytokine production without inhibition of cell growthor induction of cytotoxicity in humanl eukocytes.Onthe other hand,in the septicmousem odel,treatmentw ithani ntraperitonealapplicationo fLPS caused ac umulatived eathwithin 27 hours.The post-treatmentadministration of YC-1 significantly increased the survivalrateinendotoxemicmice. Furthermore, severalmediators weredetected and thedatashowed thatYC-1 profoundlyblockedLPS-induced NO aswellasTNF-α production,a nd prevented lung damage byhistologicale xamination.
Introduction
Septicshockisthe most common causeofdeathinintensivecare units despiterecentprogress in antibioticsand criticalcaretherapy.Numerous patients throughoutthe world sufferfrom sepsis eachyear,a nd its incidenceand mortality ratecontinuetoi ncrease ( 1) . Multiple organfailure( MOF)accounts formost of the pooroutcomesin sepsis (2) . Recently,severalaction mechanismshavebeenfocusedon,and treatmentstrategieshavebeen suggested fors epsist herapy,suchasantioxidant,a ntiinflammation,a nd inhibition of massiven itricoxide (NO)synthesis (3) (4) (5) . Clinicaltrialsof theseinnovativetherapieshavebeen conducted;however,todate,therestill havebeen no documented improvements in outcome (6) . Therefore,otheraction targets and strategiesareneeded toimprovetherapeuticeffectiveness.
Nitricoxide and guanosine 3':5'-cyclicmonophosphate (cGMP)regulatess everalf unctionsr esponding tostimuli,includingthe regulation of vasculartone and cell growth.The endotheliumsynthesizespicomolaramounts of NO undernormal physiologicalconditions.However,afterseveralpathologicalattacks,suchast raumaa nd sepsis,the exaggerated synthesisof muchlargeramounts of NO occurs (7) . Cellsrespond tobacterialproducts (suchaslipopolysaccharide [LPS] )orinflammatory cytokines(suchasinterleukin-1β and tumornecrosisfactor-α [TNF-α ])and up-regulatethe inducible NO synthase( iNOS), whichproducesmicromolaramounts of NO (8) . Therearenu-merous linesof evidencethatthe large quantitiesof NO arethe importantmediators of inflammation and contributetothe pathogenesisof vascularfailureinsepsis (9) . Itisalsoevidentthat the cytotoxiceffectisduetoacombined action of oxygen-and nitrogen-derived free radicalsand oxidants.The cytotoxicoxidant,peroxynitrite(ONOO -),formed from the reactionofNO and superoxides,accountforthisoxidativeinjury (10) . Itisconceivable thatthe inhibition of cytotoxicoxidantgeneration and prevention of the organand vascularfailureinducedbyendotoxins maybeapotentialstrategyin the treatmentof septicshockand death,a lthough antioxidantt herapyhass howno nlymodest benefitin preventing septicdeathinclinicaltrials (5) .
Bacteriaand immune responsesareknowntostronglytrigger the releaseofcytokines,whichinitiateacascade of events that leadtoactivation of the coagulation system,vasodilatation,increaseofvascularpermeability,cellularcollapse,and intensive organd amage. Inthe searchf oranti-sepsiss trategies,the immune basisof cytokine production and releaseshould betaken intoconsideration. Severalproinflammatory and antiinflammatory cytokineshavebeeninvestigated withrespecttotheireffects on MOFand mortality in patients withsepsis.Therearenumerous linesof evidencethatu p-regulated production of interleukins-1β ,-6,-8,and TNF-α serveasproinflammatory mediators and exaggeratethe progression of sepsis (11, 12) . The major antiinflammatory factorisinterleukin-10(13). Newt herapies havebeensoughtand examined toinhibitthe biologicfunction of twom ajorproinflammatory cytokines,interleukin-1β and TNF-α .Unfortunately,the anticytokine therapiesdid notshowa statisticallysignificantreduction in a28-daymortality (14) . Accordingly,ithasbeen suggested thatsystemicinflammationof sepsisrequiresmorethansingle anticytokine therapytosignificantlyimprovethe outcome.
NF-κ B, atranscription factorthatinducesthe expression of manygenesforcytokine production,plays acentralroleinthe modulation of the inflammatory and immune response. Itiswell evidentthatbacterialendotoxin isable tostimulateimmuno-responsivecellstoactivateNF-κ B, therebyincreasing the production and releasereactiono fTNF-α and iNOS, and the subsequentproduction of othermediators (15) . Therefore,N F-κ B hasbeen identified asapotentialtargetforthe developmentof newantiinflammatory strategy.
Inour laboratory,wehavedefinedthe pharmacologicalcharacterization of YC-1 (3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazol) being anovel NO-independenttype of soluble guanylyl cyclase(sGC)activator (16) . Ithasbeen suggested thatYC-1 and NO activatesGCin asynergisticmanner.Furthermore,YC-1 maypotentiatesGC activation mediated byexogenous aswellas endogenous treatmentof carbon monoxide (17) .Inthisstudy,the effectof YC-1 on LPS-induced proinflammatory and antiinflammatory cytokine releaseinhumanperipheralbloodmononuclearleukocyteshasbeenexamined. The animalsurvivalfollowing post-LPS administration of YC-1 in LPS-induced endotoxemicmicewasmonitored and the regulation of NF-κ Bactivity,iNOSexpression,NOproduction,and cytokinesreleasewere alsoexamined in an in vivo modeltoevaluatethe therapeuticpotentialofYC-1 in thetreatmentof sepsis.
Materialsand methods

Examinationofcytokinereleaseinhumanperipheral blood mononuclearleukocytes
Approximately450ml of blood wasobtained from healthy humanvolunteers.PBMCwerep repared bycentrifugation at 500 g for20min at15°Cfromdiluted blood 1:2in RPMI 1640 culturemediumo verFicollg radient(MSL;Eurobio,lesUlis, France). Cellpellets wereresuspended atafinalconcentration of 6x10 6 cells/ml. Aliquots of 500 µ lofcellsuspension weredispensedintoeachwellofa24-well plateand incubated at37°Cin the presenceofYC-1 in a5% CO 2 airincubatorin ahumidified atmosphere. 25n g/ml LPS (smooth E.coli 0111:B4) (induces IL-1β ,I L-5,I L-6,I L-8 and TNF-α cytokinesproduction) or 20 µ g/ml Concanavalin A(inducesIL-2,IL-4,IL-10and interferon-γ cytokinesproduction) combine withYC-1 werei ncubatedfor16h. Atthe end of incubation,the supernatants were collected,centrifugedat400 g for10min at15°Cand stored at -20°Cuntilcytokine determination.All cytokineswereassayed using the commercialkits provided byR&DSystems(Abingdon,UK).
Inductionofendotoxicshockand histological examination
Intheseexperiments,mice(25-30 g,ICR strain) wereseparated intothreegroupsof ten miceineachgroupand injected intraperitoneallywithLPS(60 mg/kg). TheAnimalCareCommittee of the College of Medicine,N ationalTaiwanUniversity,c onductedthe studyin accordancewiththe guideline fort he care and useoflaboratory animals.Afteratwo-orsix-hourreaction, vehicle,YC-1 (10mg/kg) orODQ (30 mg/kg),asGCinhibitor, in 0.5%carboxymethylcellulosewasorallyadministered. The survivalratewasmonitoredevery three tosixhours afterLPS injection.Beforehistologicalexamination,all micewereeuthanatized withintraperitonealadministration of pentobarbitalaftera 48-h treatmentw ithLPS.Tissuesw erefixed with4 %p araformaldehyde and embedded in paraffin. Thee mbedded tissues weresectionedat5-µ mthick,stainedwithmonoclonalantibody NF-κ Bp65( Chemicon;formerlyRoche 32N)andanalyzed using amicroscope. Inaparallel experiment,b lood samples (1 ml) werecollected beforeanimalsdied fordeterminationof plasmaNO, cGMP, and TNF-α concentrations.
Measurementof hemodynamicparameters
Male Wistarr ats (250-300g) wereanesthetized withurethane (1.0g/kg,i.p.).The tracheawasincubated tokeep the airwaypatent.Femoralarterialblood pressurewasmeasured throughPE50 tubingfilledwithheparin solution (25units/ml) connectedtoa polygraph (Lectromed,JerseyChannel Islands,UK)viaatransducer.The femoralveinwascannulated fordrugadministration. Heart ratewasderived bymeansof acardiotachometerthatwas triggered bythe arterialpressurepulse. The meanarterialblood pressure(MBP)and heart rateweremonitored.
Westernblotanalysis
All tissueswerehomogenized in lysisbuffer(10mMTris-HCl, pH7.4,150mMNaCl,1mMEGTA, 0.5 mMphenylmethylsulfonylfluoride,10 µ g/ml aprotinin,10 µ g/ml leupeptin,and 1% Triton X-100). Thehomogenatewascentrifugedat17,500 gfor 30 min,and the supernatantw ascollected forthe Westernblot analysis.Protein( 60 µ g/lane) wass eparated on a7.5% SDS-PAGE.The nitrocellulosemembrane wasimmuno-reacted with the primary antibodyt oi NOS or α -tubulin (1:1000 dilution) (SantaCruzBiotechnology)f orovernightincubation at4°C. Afterfourw ashingsw ithPBS/0.1%Tween 20,the secondary antibody(dilute1:2000)wasappliedtothe membranesfor1hat roomtemperature. Theantibody-reactivebandswereperformed withane nhanced chemiluminescencek it(Amersham,B ucks, UK).
DeterminationofNO
The amountof NO wasdeterminedfrom the accumulation of the stable NO metabolitenitritebyadding Griess reagent(1%sul-phanilamide and 0.1% naphthylethylenediamide in 5% phosphoticacid) toplasmasamples,and the absorbancewasmeasured at550nm.
Assays forcGMP and cytokine
PlasmacGMP and cytokine concentrationsweredeterminedby commercialenzyme immuno-assaykits(Amersham).
Electrophoreticmobility shiftassay
DNAbindingactivitiesof NF-κ Bweredeterminedusing electrophoreticmobility shiftassay(EMSA). Nuclearextracts were prepared and applied togel shiftassayasdescribed previously (18) . Briefly,2 µ go fn uclearextracts werei ncubated witha 35-basepairdouble-stranded 32 P-labeled probeencoding the κ B consensus sequence(5'-AGTTGA GGG GATCCC CCC AGG C-3') in the binding bufferatroom temperaturefor30min. Then, sampleswereappliedtonative5%polyacrylamide gelsand analyzedonautoradiography.
NF-κ Bp65transcriptionfactorassay
Analysisof p65binding toi ts consensus oligonucleotide was performedinlung,spleen and kidneytissuesusing anELISAbasedTrans-AM™NF-κ Bp65k it(ActiveMotif Europe,R ixensart,Belgium).
Immunohistochemistry assay NF-κ Bwasalsocharacterized byimmunohistochemistryon paraffin sections.Inbrief,5-µ mp araffin sectionsw ered eparpaffinized and endogenous peroxidasewasquenchedwith 0.3%H 2 O 2 in 100%methanol. Antigenwasunmaskedbyheating the sectionsfor15 min in 10mMcitratebufferpH6.0using amicrowave,followed by60min cooling in the same buffer.Tissueswereincubated withamonoclonalantibodythatrecognizes the activeformofNF-κ Bp65(Chemicon;formerlyRoche 32N) for45 min atr oom temperature. AstandardLSAB Technique (Dako,Glostrup,Denmark)wasused todetectthe reaction products.Sectionsw erecounterstainedwithh ematoxylin and mounted.
Statistics
Dataarepresented asthe meansplus orminus SEM forthe indicated numberof separatee xperiments.Statisticalanalysisof datawasperformedwithone-wayanalysisof variance(ANOVA ) and Bonferroni method followed bya t -test and P -valuesless than0.05wereconsidered significant.
Results
Effectof YC-1 on the regulationofcytokinereleasein humanperipheralblood mononuclearleukocytes
Toinvestigatethe effectof YC-1 on the regulation of proinflammatory and antiinflammatory cytokine release,severalcytokines wered etected in humanp eripheralbloodm ononuclearleukocytes.Asdemonstrated in Table 1 ,YC-1 exhibited differentinhibitory effects on LPS (25ng/mL)-inducedand Concanavalin A (20 µ g/mL)-induced cytokine release. Itisw orthn oting that YC-1 showed apreferentiali nhibition (15.5 to1 9.3fold) on proinflammatory cytokine release,suchasTNF-α and interleukins1 β ,6and 8,thanthoseonantiinflammatory cytokines(interleukins4and 10). However,YC-1 showed weakp otencyon the inhibition of interleukin-5release (Table 1) .
Inaparallel experiment,weused alamarBluef luorometric assays tod etermine the activity of mitochondriale nzymes, whichreducealamarBluetoafluorescentform,in humanp eripheralbloodmononuclearleukocytes.Thisassaymethod can quantitativelydetectthe cell proliferation aswellascytotoxiceffectin cells.However,neitherLPSnorConcanavalin Ainduced asignificanteffecton the mitochondrialreduction activity in thesecells,indicating thatYC-1-mediated inhibition on cytokine production wasnotthrough the influenceoncellgrowthorcytotoxiceffect(datanotshown).
Effectof YC-1 on LPS-induced animaldeath
Toinvestigatethe therapeuticpotentialofYC-1 in endotoxemic animals,anLPS-induced endotoxemicdeathinthe mousemodel wasused. Asshowed in Figure1,the intraperitonealapplication of LPS (60 mg/kg)caused acumulativeanimaldeathwithin27 hours.However,oraladministration of YC-1 atboth2and6 hours post-LPS injection significantlyincreased the survivalrate of endotoxemicmice (Fig. 1A) . Thedatademonstrated thataniTa ble 1:Effectof YC-1 on the cytokine productioninhuman peripheralblood mononuclearleukocytes. Humanperipheral blood mononuclearleukocyteswereexposed tolipopolysaccharide (LPS,25ng/ml) orConcanavalin A(20 µ g/ml) in the absenceorpresence of YC-1 for16h. Then,the cytokineproductionwasdetected using enzyme-linked immunosorbentassay(ELISA)assayasdescribed in the Methodssection. 1A) . Forhistologicale xamination,the lung, liverand kidneyt issuesw eref ixed,embedded and stained. Massiveleakagesof blood and inflammatory cellsin the lung, liverand kidneyt issuesw ereo bserved in the LPS group ( Fig.  1B) . Furthermore,in our presents tudy,YC-1 onlyinduced a small and transientdecreasei nm eanarterialblood pressure (MAP)inbothnormaland endotoxemicratmodels( Table 2) .
ExaminationofLPS-induced NO and TNF-α production
Itiswellevidentthatlarge quantitiesof NO and TNF-α production contributetothe pathogenesisof vascularfailureand severe inflammation progression in sepsis.Inresponsetoi ntraperitonealLPSadministration,amarkedelevation of plasmaTNF-α and NO levelswasdetectedinatime-dependentmanner (Fig. 2) . YC-1 alonehadlittle influenceonNO and TNF-α productions, while post-treatmentadministration of YC-1 afterLPS injection for6hours significantlyinhibited the production of these2 mediators induced byLPS (Fig. 2) .
Effectof YC-1 on LPS-induced iNOS expression
Toexamine the effectof YC-1 on iNOS protein expression,severaltissueswerecollected in eachgroupforWesternblotanalysis.Asdemonstrated in Figure3,L PS (60 mg/kg)application morethan12hours inducedaprofound increaseofiNOS protein expression in spleen (Fig. 3A) ,kidney (Fig. 3B) ,and lung tissues (Fig. 3C) . YC-1 (10mg/kg) alone hadlittle influenceoniNOS expression (lanes7and 8inFig. 3)but significantlyinhibited the LPS-induced effectwhen administered afterLPS application for 6hours,suggesting thatYC-1 regulatesupstreamsignalsof the iNOS expression pathway.
Effectof YC-1 on NF-κ BDNA binding activity Afterthe analysisof the abovedata, wefurtherexamined the effectof YC-1 on the regulation of NF-κ Bactivation in the in vivo mousemodel. Wedetected the DNAbindingactivitiesof NF-κ B using electrophoreticmobility shiftassayin nuclearextracts of lung tissues.AsshowninFigure4,LPS caused asignificantincreaseinthe level of NF-κ B/DNAcomplexafter6hours of treatmentwithYC-1,returning tobaseline thereafter.Inaddition,a densitometricevaluation of binding datawasshowed in Figure  4B , group3and 4still increaseNF-κ Ba ctivities3 -foldand 2-fold thancontrol group,separately.And YC-1 attenuated NF-κ Bactivity tobasallevel wasalsoobserved in group5and 6.Furthermore,in Figure4 C, wealsoo bserved the post-administration of YC-1 (2hafterLPSinduced) wasable tosignificantly abolishNF-κ Bactivation.Itdemonstrated thatYC-1 completely abolishedthe LPS-induced effect. Wethenexamined and quantified the effectof YC-1 on LPSmediated NF-κ BbindingtoDNAin the lung,spleen,and kidney tissues.Inthisassay,anoligonucleotide containing the NF-κ B consensus sitewasattached toplateand the p65binding to κ B oligonucleotide in tissuesamplesw asperformedand detected. The datashowed thatthe p65binding to κ Bsiteswasmaximally increased after6hours of LPS administration,and then downregulated afterthat (Fig.5) . Furthermore,LPS induced the most increaseinp65binding activityin the lungscompared withthe othertwotissues.Again,administration of YC-1 following LPS treatmentcompletelyinhibited the LPS-induced effect (Fig. 5) .
Effectof YC-1 on LPS-induced NF-κ Bexpressionin lung tissues
Todetermine whetherexpressed NF-κ B(RelA/p65) ispresentin the biopsiesof pigmented lesionsatvarious stagesof LPS treatment,immunohistochemicalstaining of paraffin-embedded lung specimensw asperformedusing aR elA/p65m onoclonal antibody.Ass howni nFigure6,the activeRelA/p65wasdis-played byLPStreatmentfor6,12and18hours (Figs.6B, 6C, and 6D, respectively).The administrationo fYC-1 followingLPS treatments ignificantlyr educed the expression of active RelA/p65inmicetreated withLPS (Figs.6Eand 6F) . However, therewaslittle activeRelA/p65being detectedinanimalstreated withYC-1 alone (Figs.6Gand 6H) .
Effectof YC-1 on LPS-induced cGMP formation
Weexamined the effectof YC-1 on LPS-induced plasmacGMP formation in an in vivo mousemodel. The datademonstrated that the injection of LPS for12to18hours inducedaprofound increaseinplasmacGMP formation (Fig. 7A) . Theadministration of YC-1 (10mg/kg) followingLPStreatments ignificantlyinhibited LPS-induced effect (Fig. 7A) . Wealsodemonstrated that ODQ didnotsuppress theYC-1-mediatedcGMPformation in in vivo assay (Fig. 7B) . ThedataareconsistentwiththoseonNO formation demonstrated in Figure2C.Inthiss tudy,YC-1,b y itself,did notmodifycGMPcontentwhile significantlyinhibit LPS-induced cGMP formation,suggesting thatYC-1-mediated effectwasnotthrough acGMP-elevating pathway.
Discussion
Cytokinesareendogenous mediatorsthatplayanimportantrole in coordinating the inflammatory signaling in the humanbody (19) . Thegeneration of proinflammatory (TNF-α ,interferon-β , and interleukins1 β ,2,and 8) and antiinflammatory (interleukins 4and 10)cytokinesisstrictlyregulated bycomplicated mechanismsin severald iseases (20) (21) (22) . Theantiinflammatory cytokinesaregenerated forthe cessation orattenuation of inflammatory progression toretain the function of vitalo rgans (20, 21, 23) . Thesestudiesprovide evidencethatthe targeton cytokine production,eitherthe inhibition on proinflammatory cytokines ort he potentiation on antiinflammatory cytokines,mightbea potentialstrategyforthe prevention of MOFand septicdeath. In thisstudy,LPS and Concanavalin Awereused tostimulatethe production and releaseofcytokinesin humanperipheralblood mononuclearleukocytes.The datademonstrated thatYC-1 showed amorepotentinhibition on the proinflammatory cytokinest hano nthe antiinflammatory cytokines.Furthermore,it hasbeen reported thatagood correlation existsbetweenh igh proinflammatory cytokine/antiinflammatory cytokine ratio and pooroutcomesin patients withsystemicinflammatory response suchassepsis (23, 24) . Inthisstudy,YC-1 showed a15.5-fold to 19.3-fold preferentiali nhibition on proinflammatory cytokine release. ItissuggestedthatYC-1 mayplayabeneficialroleon the prevention of inflammatory progress. The endotoxinLPSisamajorcomponentof the outermembranesof Gram-negativebacteria.Ithasbeenshownthatpatients withGram-negativesepticemiaelicitmoreproinflammatory cytokineproduction and havemoreillness thanthosewithGrampositivesepticemia (23) . Todetermine the therapeuticpotential of YC-1 in sepsis,the LPS-induced endotoxemicdeathi nthe mousemodel wasused. Thedatashowed thatthe post-administration of YC-1 afterLPS application significantlyincreased the survivalrateo fe ndotoxemicmice. Furthermore,thesurvival ratewasbetterbypost-administration of YC-1 at6hours thanat 2hours.Itmightbeexplained bythe pharmacokineticproperty sinceo rallyappliedYC-1 hadarapido nset(lesst han1 0min-utes)but short half-life (about one hour).Itw asevidentin this studythatall of the LPS-mediated events,suchasNF-κ Bactivation,iNOS expression,aswellasNO over-production,and cytokinereleasereaction,occurredmaximallyafter6to12hours of LPS application in mice. However,the 6 th hour post-administration ofYC-1 afterLPS injection could optimizeYC-1 action.
Advancesin the realization of complicated biologicalp rocessesresponsible forthe clinicalsyndrome of sepsishaveled to the developmentof numerous therapeutictargets,suchasendotoxin,inflammatory cytokines,b ioactivel ipid mediators,N O, and downstreamcoagulation response (25) . Alotof studiesdirectedagainst thesetargets havedemonstrated markedeffectin septica nimalm odels; however,in humans,the outcomeshave beenonlymodest (25) . One of the most convincing explanations isthatthe pathogenesisof sepsisismultifactorialand itrequires morethansingle therapyagainst the mentioned targets.The most prominenteffectof NO isthe activation of guanylatecyclaseand the followingcGMPproduction,whichresults in the vasodilatation thatischaracteristicof septicshock. Inthisstudy,theNO production and cGMP synthesisoccurredm aximallyafter12 hours of LPS application in endotoxemicmousem odels.The post-administrationo fYC-1 significantlyinhibited LPS-induced effects.Inafurtherinvestigation,YC-1 dramaticallyinhibited LPS-induced iNOSexpression in spleen,kidney,a nd lung tissuesin mice,indicatingthatYC-1 iseffectiveonthisNO target.However,itisw orthnoting thatYC-1 isasGC activator and mayactivatesGCin asynergisticmannerin combination withNO donors (16) . One hypothesismightbethatYC-1 deterioratest he hypotensivee ffectduring septicshock. Inthis study,YC-1 aloneinducedamoderatebut insignificantincrease of cGMP synthesisandODQ, asGC inhibitor,did notr everse YC-1-mediated animalsurvivalrateand nors uppress the YC-1-mediated cGMP formationi n in vivo assay,whereasprofoundlyinhibited LPS-mediated cGMPproduction suggesting thatYC-1 induced thee ffectin thiss tudyw asnott hrough a cGMP-elevating mechanism. Furthermore,in our study,YC-1 onlyinduced asmall and transientdecreasei nm eanarterial blood pressure(MAP)inbothnormaland endotoxemicratmodels.Thesedataaresimilartothosereported byRothermund and colleaguesthatYC-1 causesashort-term(less than10min) decreaseofMAP in boththe hypertensiveandnormotensiverats (26) . Thismaypartlyexclude the possibilityof YC-1 on the deterioration of septicshock.
According tothe diverseeffects of YC-1 on the inhibition of bothiNOS expression and cytokine production,acommon upstreamsignaling of transcription wasexamined. Therearemany linesof evidencesuggesting thatt he engagementof endotoxin on immune-related cellsinducesnumerous signaling cascades thatcausen ewgene expressionst hrough NF-κ Ba ctivation. iNOSand TNF-α aretwooftheprominentNF-κ B-mediated cellularproducts thatareresponsible forvascularfailureand MOF in septicshock (15, 22, 23, 25) . Wefurtherexamined the effectof YC-1 on the regulation of NF-κ Bactivation in the in vivo mouse models.The datashowed thatYC-1 completelyabolishedLPSinduced p65binding to κ Boligonucleotide in the lung,spleen, and kidneytissues,although LPS induced the most increasein p65binding activityin lung tissuesin theseendotoxemicmice. Forfurtherconvincing determination,animmunohistochemical staining of paraffin-embedded lung specimensw asperformed using aR elA/p65m onoclonalantibody.The dataa lsod emonstrated thatthe post-administration of YC-1 afterLPS treatment significantlyreduced the expression of activeRelA/p65inLPS-treated mice. ItissuggestedthatYC-1 inhibits iNOS expression and proinflammatory cytokine production through the suppression on NF-κ Bactivation and proteinexpression.
One potentialtreatmentstrategyin septicshockhasbeenfocusedo ncoagulation target (27) (28) (29) . Ino ur previous studies, YC-1 hasbeenexamined toshowanantithromboticeffectin several in vivo modelsand adecreaseinmortality in fatalpulmonary thromboembolismmodel (30).Furthermore,in the studyby Cauwels(31),the pretreatmentw ithm ethylene bluecane fficientlypreventTNF-induced cGMP accumulation,bradycardia, hypotension,and mortality.Our dataarenotin conflictwiththeir studys inceYC-1 significantlyinhibits LPS-induced cGMP formation,a lthough thiseffectisnoty etidentifiedtobeattributed tothe potentialbenefitof YC-1 ornot.However,we could notrule out anyotherpotentialmechanismofYC-1 since ithasbeen suggested thatYC-1 inhibits fMLP-induced superoxide anion O 2 -generation in ratneutrophils(32)andi nhibits thromboticeffectin mice( 30). Thesebiologicalactivitiesof YC-1 canalsocontributetothe potentialbenefitin the treatment of sepsis.
Insummary,the datademonstratesthatYC-1 preferentially blocksthe proinflammatory cytokine releaseinhumanperipheralblood mononuclearleukocytes.The administrationofYC-1 followingLPStreatments ignificantlyinhibits NF-κ Ba ctivation,iNOS expression,NOover-production,and cytokine releasereactioninan in vivo model,and furthermore,increasesthe survivalo fe ndotoxemicmice. Incombinationwithi ts antithromboticand profibrinolyticproperties,wesuggest thatYC-1 maybeapotentialsmall molecule agentforthe therapeutictreatmentof sepsis.
